Types of relaxation techniques, which can help cancer patients

Cancer detection and following treatments lead to emotional stress. Patients worry constantly about their current situation and how it lowers their quality of life. Some of them are not able to return to work and school, while some no longer can; take part in social activities Therefore they feel socially isolated. It is at this point that they need more help from friends and family. To combat stress more effectively, they require relaxation techniques but. They act directly as alternative cancer therapies, but they help reduce symptoms in reducing the burden of cancer patients, as well as cancer. Some of them are:

Deep breathing exercise

Shallow breathing, which is brought on by fear, leads to an accumulation of carbon dioxide in the body. Deep breathing exercise, you will make sure feel. Simply breathing deeply from your diaphragm. Keep it for as long as you can then gently exhale. Repeat the process several times until you feel calm.

Images by

As the term suggests, creates images images on your mind. You can first lying on the bed and close your eyes. Imagine a place synonymous with beauty and tranquility as directly on the beach. Imagine that you are resting on a hammock, experience and enjoy the waves as they dance and sing a quiet song. Visualize your family and have fun with the waves because they like to swim in the crystal clear water. Remember her laughter. Detect as open your eyes and bring you back to reality, you feel much better.

You can choose to perform the images in front of the hospital for your regular treatment sessions. This will somehow brighten mood, making you more positive about what you are doing. You will be surprised to notice that you don't feel so stressful as before. This may be no direct alternative cancer treatment, but it certainly improves your well-being, contributing much of the manner, as you are dealing with cancer treatments.

Progressive muscle relaxation

Includes specific muscle groups avoid this form of relaxation technique, and then enable to relax them. As you do this, lie down on the bed. Make sure that you are in a comfortable position and clothing. Close your eyes and feel the silent place. Think to yourself.

First, fold the forehead. Let your eyebrows to reach your hairline. Stay in this pose for five seconds, then relax. Focus on your eyes. Close properly (you will realize that your nose will be moved also). Scowl and you move the muscles in your lips, cheeks and jaw. Stretch your arms forward when pressing your fists. The relaxation you feel in your hands. Follow this up, because to build tension in the forearms, upper arms, shoulders, back, abdomen, hips and buttocks, thighs, feet and toes. If you keep some muscles feel tense feel, go back and do this again two-to three times.

It is but natural for cancer patients as you are looking to alternative cancer therapies, because you are hoping to improve your chances for survival. Relaxation one way to improve the condition, that really is on how you answer to cancer therapies help.

View the original article here

Blocking The Protein-Protein Interaction Which Causes Ewing Sarcoma

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 17 May 2013 - 0:00 PDT Current ratings for:
Blocking The Protein-Protein Interaction Which Causes Ewing Sarcoma

Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Their study, which will be presented at the 2013 annual meeting of the American Society of Clinical Oncology*, provides pre-clinical evidence necessary to initiate a clinical trial.

"This agent has the potential to be more effective, and considerably less toxic, than the current drugs now used to treat this rare cancer," says the study's lead investigator, Jeffrey Toretsky, MD, a pediatric oncologist and researcher at Georgetown Lombardi, part of Georgetown University Medical Center.

The agent, (S)-YK-4-279, was developed by Toretsky and his colleagues, including scientists in GUMC's Center for Drug Discovery. Based on early promising studies of the compound, Toretsky established TDP Biotherapeutics, Inc. to manufacture the agent. Toretsky says TDP Biotherapeutics, Inc. is preparing a U.S. Food and Drug Administration (FDA) investigational new drug (IND) application for (S)-YK-4-279 so that a clinical trial can be initiated.

In the United States, about 500 children and young adults are diagnosed with the cancer annually, and they are treated with a combination of five different chemotherapy drugs. Between 60 to 70 percent of patients survive more than five years, but with many late effects from therapy. Few treatments lead to a cure for patients whose cancer progresses, Toretsky says.

Ewing sarcoma is caused by the exchange of DNA between two chromosomes. The resulting EWSR1-FLI1 gene produces a fusion protein, EWS-FLI1, responsible for development of the cancer. In 2006, Toretsky and his team discovered that the fusion protein binds to another protein, RNA helicase A (RHA), which is important for cancer progression.

The (S)-YK-4-279 agent they developed is considered unique because it stops the two proteins - EWS-FLI1 and RHA - from interacting. "Scientists have long thought it impossible to block protein-protein interaction because the surface of these proteins are too slippery and flexible for a drug to bind to," Toretsky says. "Our agent challenges that conventional thinking."

To test the agent, the researchers developed a rat model of Ewing sarcoma and figured out how to deliver a continuous drip of the drug to the animals. "We found that cancer cells need a continuous exposure at low concentrations for the drug to be of maximum effectiveness," Toretsky says. "And this strategy works extremely well in these animal models. The drug appears to be very successful."

Toretsky is an inventor on a patent application that has been filed by Georgetown University related to the technology described. He has an ownership interest in TDP Biotherapeutics, to which the technology has been licensed for research and development.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. ASCO Annual Meeting: May 31-June 4, 2013 | McCormick Place | Chicago, Illinois

The FDA has granted the TDP Biotherapeutics company orphan drug status (Orphan Drug Act), which qualifies the sponsor of a product to receive tax credit and marketing incentives. The study was funded by a grant from the National Cancer Institute (RC4 CA156509) issued under the American Recovery and Reinvestment Act (R01CA138212).

Georgetown University Medical Center

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Georgetown University Medical Center. "Blocking The Protein-Protein Interaction Which Causes Ewing Sarcoma." Medical News Today. MediLexicon, Intl., 17 May. 2013. Web.
20 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Blocking The Protein-Protein Interaction Which Causes Ewing Sarcoma'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here